Cutaneous Side Effects of Targeted Therapy and Immunotherapy for Advanced Melanoma-Reference-Cited by-同舟云学术

Cutaneous Side Effects of Targeted Therapy and Immunotherapy for Advanced Melanoma

Published:2018-12-30 Issue: Volume:2018 Page:1-7
ISSN:2090-908X
Container-title:Scientifica
language:en
Short-container-title:Scientifica

Author:

Russo Irene¹,Zorzetto Ludovica¹,Chiarion Sileni Vanna²,Alaibac Mauro¹^ORCID

Affiliation:

1. Unit of Dermatology, University of Padua, Via Gallucci 4, 35128 Padova, Italy

2. Istituto Oncologico Veneto I.R.C.C.S., Via Gattamelata 64, 35128 Padova, Italy

Abstract

Melanoma is one of the most fatal cancers, and its incidence is increasing worldwide. Thanks to the better understanding of the molecular mechanisms involved in the pathogenesis of melanoma, recently new targeted agents have been developed. In this article, we review the current state of knowledge of clinical presentation, mechanisms, and management of the most common cutaneous side effects observed during treatment with targeted and immunological therapies approved for advanced melanoma. We include discussion of BRAF/MEK inhibitors and immune-checkpoint inhibitors, notably CTLA-4 and PD-1 inhibitors.

Publisher

Hindawi Limited

Subject

General Agricultural and Biological Sciences,General Environmental Science

Link

http://downloads.hindawi.com/journals/scientifica/2018/5036213.pdf

Reference51 articles.

1. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2012

2. The role of BRAF V600 mutation in melanoma

3. BRAF Signaling and Targeted Therapies in Melanoma

4. Mutations of the BRAF gene in human cancer

5. Targeting the RAS pathway in melanoma

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The possible and intriguing relationship between bullous pemphigoid and melanoma: speculations on significance and clinical relevance;Frontiers in Immunology;2024-08-29

2. Toxicities from BRAF and MEK Inhibitors: Strategies to Maximize Therapeutic Success;Current Oncology Reports;2024-06-08

3. BRAFV600E Metastatic Melanoma Journey: A Perspective from a Patient and his Oncologist;Advances in Therapy;2024-05-28

4. Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice;Melanoma Research;2023-08-03

5. Diagnosis and Management of Dermatologic Adverse Events from Systemic Melanoma Therapies;American Journal of Clinical Dermatology;2023-07-03